We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Platelet Size Predicts Mortality in Patients with Sepsis

By LabMedica International staff writers
Posted on 26 Jul 2012
A new study suggests that the mean platelet volume (MPV) is an easily accessible prognostic marker of mortality in sepsis.

Researchers at Klinikum St. More...
Georg (Leipzig, Germany) conducted a study involving 191 patients (median age 72, 38% women) with documented sepsis. The researchers prospectively evaluated MPV at admission, at the onset of sepsis, at the diagnosis of sepsis, and during the course of the disease, as a marker for the prediction of outcomes. These data were compared with data from 56 patients (median age was 74, 45.5% women) with acute upper and lower gastrointestinal (GI) bleeding, who served as control subjects. Data on other standard laboratory biomarkers and clinical parameters were collected at the same time.

The results showed MPV on admission and at the onset of symptoms was strongly associated with death. Of 183 sepsis patients, 41 (21.5%) that died had a higher MPV than survivors (9.6 vs. 9.19 femtoliter (fL), respectively). At the time of positive blood cultures, those values had increased (11.2 vs. 9.7 fL).

Parameters of temperature, leukocyte count, lactate, procalcitonin, and C-reactive protein (CRP) values, on the other hand, were not at all predictive of outcome. The researchers then determined that the best predictor of death or survival was when they used an MPV discriminatory value of 8.7 fL. The study was presented as poster session at the 15th International Congress on Infectious Diseases, held during June 2012 in Bangkok (Thailand).

“This figure is at the high end of the normal range of platelet volumes, but is still highly predictive of poor outcome, namely death, in patients with sepsis,” said lead author and study presenter Thomas Grünewald, MD, PhD, head of the division of infectious diseases and tropical medicine. “We saw that patients with MPVs higher than 8.7 are much more prone — the odds ratio is 3.2 — to worse outcomes (for example, death) than patients with MPVs lower than 8.7.”

MPV is a machine-calculated measurement of the average size of platelets found in blood and is typically included in blood tests as part of the CBC. Since the average platelet size is larger when the body is producing increased numbers of platelets, the MPV test results can be used to make inferences about platelet production in bone marrow or platelet destruction problems. A typical range of platelet volumes is 9.7–12.8 fL, equivalent to spheres 2.65 to 2.9 µm in diameter.

Related Links:

Klinikum St. Georg





Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
New
Portable POCT Blood Gas Analyzer
BD100
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.